ZFIN ID: ZDB-PUB-200710-28
GSTM3 variant is a novel genetic modifier in Brugada syndrome, a disease with risk of sudden cardiac death
Juang, J.J., Binda, A., Lee, S.J., Hwang, J.J., Chen, W.J., Liu, Y.B., Lin, L.Y., Yu, C.C., Ho, L.T., Huang, H.C., Chen, C.J., Lu, T.P., Lai, L.C., Yeh, S.S., Lai, L.P., Chuang, E.Y., Rivolta, I., Antzelevitch, C.
Date: 2020
Source: EBioMedicine   57: 102843 (Journal)
Registered Authors: Lee, Shyh-Jye
Keywords: Brugada syndrome, Genetics, Inherited cardiac arrhythmia, Sudden cardiac death
MeSH Terms:
  • Adult
  • Animals
  • Arrhythmias, Cardiac/genetics*
  • Arrhythmias, Cardiac/pathology
  • Asian Continental Ancestry Group/genetics
  • Brugada Syndrome/complications
  • Brugada Syndrome/genetics*
  • Brugada Syndrome/pathology
  • DNA Copy Number Variations/genetics
  • Death, Sudden, Cardiac*
  • Electrocardiography
  • Exons/genetics
  • Female
  • Genes, Modifier/genetics
  • Genetic Predisposition to Disease*
  • Genotype
  • Glutathione Transferase/genetics*
  • HEK293 Cells
  • Humans
  • Male
  • Mutation/genetics
  • Phenotype
  • Taiwan
  • Whole Exome Sequencing
  • Zebrafish/genetics
PubMed: 32645615 Full text @ EBioMedicine
Brugada syndrome (BrS) is a rare inherited disease causing sudden cardiac death (SCD). Copy number variants (CNVs) can contribute to disease susceptibility, but their role in Brugada syndrome (BrS) is unknown. We aimed to identify a CNV associated with BrS and elucidated its clinical implications.
We enrolled 335 unrelated BrS patients from 2000 to 2018 in the Taiwanese population. Microarray and exome sequencing were used for discovery phase whereas Sanger sequencing was used for the validation phase. HEK cells and zebrafish were used to characterize the function of the CNV variant.
A copy number deletion of GSTM3 (chr1:109737011-109737301, hg38) containing the eighth exon and the transcription stop codon was observed in 23.9% of BrS patients versus 0.8% of 15,829 controls in Taiwan Biobank (P < 0.001), and 0% in gnomAD. Co-segregation analysis showed that the co-segregation rate was 20%. Patch clamp experiments showed that in an oxidative stress environment, GSTM3 down-regulation leads to a significant decrease of cardiac sodium channel current amplitude. Ventricular arrhythmia incidence was significantly greater in gstm3 knockout zebrafish at baseline and after flecainide, but was reduced after quinidine, consistent with clinical observations. BrS patients carrying the GSTM3 deletion had higher rates of sudden cardiac arrest and syncope compared to those without (OR: 3.18 (1.77-5.74), P<0.001; OR: 1.76 (1.02-3.05), P = 0.04, respectively).
This GSTM3 deletion is frequently observed in BrS patients and is associated with reduced INa, pointing to this as a novel potential genetic modifier/risk predictor for the development of the electrocardiographic and arrhythmic manifestations of BrS.
This work was supported by the Ministry of Science and Technology (107-2314-B-002-261-MY3 to J.M.J. Juang), and by grants HL47678, HL138103 and HL152201 from the National Institutes of Health to CA.